Wittekind Amends Renovaro Inc. 13D Filing

Ticker: LNAI · Form: SC 13D/A · Filed: May 17, 2024 · CIK: 1527728

Renovaro Inc. SC 13D/A Filing Summary
FieldDetail
CompanyRenovaro Inc. (LNAI)
Form TypeSC 13D/A
Filed DateMay 17, 2024
Risk Levelmedium
Pages5
Reading Time6 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 13D-filing, beneficial-ownership, amendment

Related Tickers: RNO

TL;DR

Wittekind updated his stake in Renovaro Inc. (RNO) via 13D filing.

AI Summary

William Anderson Wittekind filed an amendment (No. 16) to Schedule 13D on May 17, 2024, for Renovaro Inc. The filing indicates a change in beneficial ownership of the company's common stock. Wittekind's address is listed as 8581 Santa Monica Blvd. #317, West Hollywood, CA 90069.

Why It Matters

This amendment signals a potential shift in control or significant stakeholding in Renovaro Inc., which could impact the stock price and future corporate actions.

Risk Assessment

Risk Level: medium — Amendments to Schedule 13D often indicate significant changes in beneficial ownership, which can lead to increased volatility.

Key Players & Entities

  • William Anderson Wittekind (person) — Filer and beneficial owner
  • Renovaro Inc. (company) — Subject company
  • 29350E 104 (other) — CUSIP Number for Renovaro Inc. common stock
  • Patrick T. McCloskey (person) — Legal counsel for filer

FAQ

What is the specific change in beneficial ownership reported in this Amendment No. 16?

The filing is an amendment to Schedule 13D and does not specify the exact percentage or number of shares changing beneficial ownership in the provided text, but indicates a change has occurred.

When was this amendment filed with the SEC?

This amendment was filed on May 17, 2024.

What is the CUSIP number for Renovaro Inc. common stock?

The CUSIP number for Renovaro Inc. common stock is 29350E 104.

Who is listed as the filer for this Schedule 13D amendment?

William Anderson Wittekind is listed as the filer.

What was Renovaro Inc. formerly known as?

Renovaro Inc. was formerly known as Renovaro Biosciences Inc. and Enochian Biosciences Inc.

Filing Stats: 1,601 words · 6 min read · ~5 pages · Grade level 8.7 · Accepted 2024-05-17 21:37:53

Key Financial Figures

  • $0.0001 — ame of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 29350

Filing Documents

Purpose of Transaction

Item 4. Purpose of Transaction The information in Item 6 of this Amendment No. 16 is hereby incorporated by reference into this Item 4.

Interests in Securities

Item 5. Interests in Securities of the Issuer (a)-(b)The information in Items 7-11 and Item 13 of the cover page of this Amendment No. 16, including the accompanying footnotes, is hereby incorporated by reference into this Item 5. (c) None. (d) Not applicable. (e) Not applicable.

. Contracts, Arrangements, Understandings

Item 6 . Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer. Denial of Rule 11 Motion On April 11, 2024 legal counsel for the Board Defendants filed a Reply to Wittekind’s and Weird Science’s Rule 11 Opposition and a Declaration in Support of such Reply with the California District Court for the Central District. The Reply to the Rule 11 Opposition is attached to this Amendment No. 16 as Exhibit 22 and the Declaration in Support of such Reply is attached to this Amendment No. 16 as Exhibit 23. 3 On May 16, 2024 the California District Court for the Central District issued an order denying the Rule 11 Motion. A copy of such order is attached to this Amendment No. 16 as Exhibit 24. Stockholder Derivative Complaint In accordance with the May 16, 2024 order denying the Rule 11 Motion, Wittekind and Weird Science intend to amend the Stockholder Derivative Complaint no later than May 31, 2024, or by a date otherwise permitted by the Court. Resales of Common Stock To the extent any shares of Common Stock owned by Weird Science, Wittekind or the Trusts are included in a registration statement that is filed by the Issuer and declared effective by the SEC (including, without limitation, the Form S-1 that the Issuer agreed to file to register resales by Lincoln Park Capital Fund LLC pursuant to the Registration Rights Agreement between the Issuer and Lincoln Park dated June 20, 2023), Weird Science, Wittekind and the Trusts (as applicable) intend to resell shares under such registration statement(s) in accordance with the Investor Rights Agreement. In addition, Wittekind intends to (individually and on behalf of Weird Science), and may cause the Trusts to, resell shares of Common Stock from time to time in accordance with Rule 144 under the 1933 Act.

Material

Item 7. Material to be Filed as Exhibits Exhibit 22 Board Defendants’ Reply in Further Support of Motion For Sanctions Against Plaintiffs and Plaintiffs’ Counsel filed with the United States District Court for the Central District of California–Western Division, on April 11, 2024. Exhibit 23 Declaration of Michael J. Quinn in Support of Reply filed with the United States District Court for the Central District of California–Western Division, on April 11, 2024.* Exhibit 24 Order Denying Defendants’ Motion for Sanctions issued by the United States District Court for the Central District of California on May 16, 2024. * Exhibit A to this Exhibit has been omitted pursuant to Item 601(a)(5) of Regulation S-K (17 CFR §229.601(a)(5)) but will be furnished supplementally to the SEC upon request. 4 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Amendment No. 16 is true, complete and correct. Date: May 17, 2024 /s/ William Anderson Wittekind WILLIAM ANDERSON WITTEKIND 5

View Full Filing

View this SC 13D/A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.